You are here

Keytruda

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star

Endpoints

Flag link:

Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs

Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs

Fierce Pharma

drug manufacturing

Flag link:

Merck quarterly profit beats on Keytruda demand

Merck quarterly profit beats on Keytruda demand

Yahoo/Reuters

Flag link:

5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them

5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them

Motley Fool

Bristol-Myers Squibb

Flag link:

Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda

Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda

GoinPharma

non-squamous cell non-small cell lung cancer

Flag link:

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

GoinPharma

Bristol-Myers Squibb

Flag link:

Merck's Keytruda extends lung cancer survival in combination trial

Merck's Keytruda extends lung cancer survival in combination trial

Yahoo/Reuters

clinical trials

Flag link:

Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return

Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Fierce Pharma

Flag link:

Cancer Space Update: New Regulatory Status for 3 Major Drugs

Cancer Space Update: New Regulatory Status for 3 Major Drugs

Yahoo/Zacks.com

Seattle Genetics

Flag link:

One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

Endpoints

clinical trials

Flag link:

Why 2017 Was a Year to Forget for Merck & Co. Inc.

Why 2017 Was a Year to Forget for Merck & Co. Inc.

Motley Fool

Flag link:

Recent Developments for Merck’s Keytruda

Recent Developments for Merck’s Keytruda

Market Realist

immuno-oncology

anti-PD-1 immunotherapy

non-small cell lung cancer

Flag link:

How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas

How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas

Fierce Pharma

Bristol-Myers Squibb

Gilead Sciences

Flag link:

Here's Why Merck & Co., Inc. Tanked 14% in October

Here's Why Merck & Co., Inc. Tanked 14% in October

Motley Fool

non-small cell lung cancer

Flag link:

OncoSec shares turn hot as microcap reports promising PhII data for an I/O one-two punch

OncoSec shares turn hot as microcap reports promising PhII data for an I/O one-two punch

Endpoints

clinical trials

ImmunoPulse IL-12

Flag link:

Merck Has Good Reasons for Its Keytruda Delay

Merck Has Good Reasons for Its Keytruda Delay

Bloomberg

Flag link:

Why What’s Bad for Merck Is Good For Bristol-Myers

Why What’s Bad for Merck Is Good For Bristol-Myers

Barron's

Bristol-Myers Squibb

Flag link:

3 Bright Spots in Merck's Q3 Results

3 Bright Spots in Merck's Q3 Results

Motley Fool

Flag link:

Merck Keytruda sales soar, but European application pulled

Merck Keytruda sales soar, but European application pulled

Yahoo/Reuters

Flag link:

Pages